SCHEMBL8768976

SCHEMBL8768976

Nc1ccc2[nH]c(-c3ccc(Oc4ccc(-c5nc6cc(N)ccc6[nH]5)cc4)cc3)nc2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 1/20 0.78
CHEK2 O96017 6/20 0.70
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
RXFP1 Q9HBX9 2/20 0.61
CACNA1B Q00975 1/20 0.61
APBA1 Q02410 1/20 0.61
ALDH1A1 P00352 6/20 0.59
SMN1; SMN2 Q16637 6/20 0.59
NPC1 O15118 5/20 0.59
KDM4E B2RXH2 5/20 0.59
MAPT P10636 5/20 0.59
RAB9A P51151 4/20 0.59
GLA P06280 3/20 0.59
GFER P55789 3/20 0.59
GAA P10253 3/20 0.59
RECQL P46063 2/20 0.59
HPGD P15428 5/20 0.57
POLB P06746 3/20 0.57
TP53 P04637 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31060757 0.94 CHEK2 (0.80) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL13963972 0.92 HPSE (0.67) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL30533210 0.90 MEN1 (0.73) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL1655753 0.90 MEN1 (0.73) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL159873 0.89 ALDH1A1 (0.74) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL28312335 0.89 ALDH1A1 (0.74) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL8769051 0.89 MEN1 (0.71) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL30307784 0.89 ALDH1A1 (0.74) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL1662751 0.88 NPC1 (0.70) HPSECHEK2MEN1KMT2ARXFP1
SCHEMBL28567556 0.86 HPSE (0.97) HPSECHEK2MEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200093852-A1 Methods of Treating Ocular Disorders Beta Therapeutics Pty Ltd (AU) 2020-03-26 US disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL HPSE 354/4885CHEK2 4422/4885MEN1 1370/4885
US-20200093852-A1 Methods of Treating Ocular Disorders ALDH1A2, HPSE, RB1 HPSE 2/4885CHEK2 1935/4885MEN1 3872/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF HPSE 635/4885CHEK2 3203/4885MEN1 1395/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF HPSE 635/4885CHEK2 3203/4885MEN1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.